Being a Life Sciences Leader

Fred Vogt, Iovance Biotherapeutics

Life Sciences Pennsylvania Season 7 Episode 5

This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award. 

In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.